SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-23-039875
Filing Date
2023-05-15
Accepted
2023-05-15 16:49:26
Documents
49
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0323_biondvax.htm   iXBRL 10-Q 432071
2 CERTIFICATION f10q0323ex31-1_biondvax.htm EX-31.1 7953
3 CERTIFICATION f10q0323ex31-2_biondvax.htm EX-31.2 7885
4 CERTIFICATION f10q0323ex32-1_biondvax.htm EX-32.1 3388
5 CERTIFICATION f10q0323ex32-2_biondvax.htm EX-32.2 3432
  Complete submission text file 0001213900-23-039875.txt   2740551

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE adr-20230331.xsd EX-101.SCH 45526
7 XBRL CALCULATION FILE adr-20230331_cal.xml EX-101.CAL 23651
8 XBRL DEFINITION FILE adr-20230331_def.xml EX-101.DEF 137434
9 XBRL LABEL FILE adr-20230331_lab.xml EX-101.LAB 329087
10 XBRL PRESENTATION FILE adr-20230331_pre.xml EX-101.PRE 150468
43 EXTRACTED XBRL INSTANCE DOCUMENT f10q0323_biondvax_htm.xml XML 189575
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37353 | Film No.: 23923669
SIC: 2836 Biological Products, (No Diagnostic Substances)